ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ARGENX SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026
$825.61+6.47 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 42.2
- Dividend yield
- –
ARGENX SE revenue by segment
By business segment
By product or service
By region
| Revenue | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| United States | $30.00M | – | $317.40M | $40.90M | $76.29M | 84.4% | – |
| China | $5.53M | $4.24M | $178.37M | – | – | 15.6% | +30.6% |
| Denmark | – | $5.37M | $1.39M | $342.00K | $488.00K | – | – |
| Belgium | – | – | – | – | $1.68M | – | – |
| Other | – | $424.00K | $123.00K | – | – | – | – |
From the segment and revenue-disaggregation notes of Argenx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.